24
Participants
Start Date
April 12, 2019
Primary Completion Date
May 15, 2019
Study Completion Date
June 15, 2019
Omnipaque™ (iohexol) Injection
755 mg/mL iohexol (350 mgI/mL), 80 mL infused intravenously over approximately 20 seconds
CE-Iohexol
755 mg/mL iohexol (350 mgI/mL)/50 mg CAPTISOL®/mL, 80 mL infused intravenously over approximately 20 seconds
Syneos Health Clinique, Québec
Lead Sponsor
Collaborators (2)
Ligand Pharmaceuticals
INDUSTRY
Syneos Health
OTHER
CyDex Pharmaceuticals, Inc.
INDUSTRY